Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).

ABSTRACT:

Background and aims

Evidence suggests that both the nicotinic receptor α5 subunit (CHRNA5) and Cytochrome P450 2A6 (CYP2A6) genotypes influence smoking cessation success and response to pharmacotherapy. We examine the effect of CYP2A6 genotype on smoking cessation success and response to cessation pharmacotherapy, and combine these effects with those of CHRNA5 genotypes.

Design

Placebo-controlled randomized smoking cessation trial.

Setting

Ambulatory care facility in Wisconsin, USA.

Participants

Smokers (n = 709) of European ancestry were randomized to placebo, bupropion, nicotine replacement therapy or combined bupropion and nicotine replacement therapy.

Measurements

Survival analysis was used to model time to relapse using nicotine metabolism derived f

SUBMITTER: Chen LS 

PROVIDER: S-EPMC3946972 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature